Flamingo Pharmaceuticals Ltd: Company Profile

Background

Overview

Flamingo Pharmaceuticals Ltd, established in 1985, is a Mumbai-based pharmaceutical company committed to providing affordable and high-quality medicines globally. The company has expanded its presence to over 50 countries across five continents, including regions in Asia, Africa, Central America, and the Commonwealth of Independent States (CIS).

Mission and Vision

Mission: To delight partners through ethical business practices by offering quality products at affordable prices.

Vision: To be a well-known global player by meeting quality standards.

Industry Significance

Flamingo Pharmaceuticals has established itself as a significant player in the generic pharmaceutical industry, supplying a diverse range of formulations to various international markets. Its adherence to international quality standards has facilitated its entry into regulated markets, including Europe and the United States.

Key Strategic Focus

Core Objectives

Flamingo Pharmaceuticals aims to expand its global footprint by enhancing its presence in regulated markets and strengthening its contract manufacturing services. The company focuses on delivering high-quality, affordable medicines to meet the diverse healthcare needs of its international clientele.

Areas of Specialization

Contract Manufacturing: Providing contract development and manufacturing services to partners in the European Union, United Kingdom, and Australia.

Generic Medicines: Developing and marketing a wide range of generic medicines across key therapeutic areas.

Key Technologies Utilized

Flamingo Pharmaceuticals employs advanced manufacturing technologies to ensure the production of high-quality pharmaceutical products. The company adheres to international quality standards, including WHO-GMP, UK-MHRA, USFDA, and EU-GMP, to maintain the efficacy and safety of its products.

Primary Markets Targeted

The company targets both regulated and semi-regulated markets, including Europe, the United States, Africa, Southeast Asia, and Central America, aiming to provide accessible healthcare solutions globally.

Financials and Funding

Funding History

Flamingo Pharmaceuticals is a privately held company and has not publicly disclosed detailed funding history or financial statements. The company operates with an authorized capital of ₹10.00 crore and a paid-up capital of ₹6.80 crore.

Recent Financial Performance

In the financial year ending March 31, 2024, Flamingo Pharmaceuticals reported a 1.28% decrease in total revenue compared to the previous year. The company's profit declined by 58.24%, and its net worth increased by 2.38%.

Pipeline Development

Flamingo Pharmaceuticals offers a diverse portfolio of generic medicines across various therapeutic areas. The company is actively involved in the development and marketing of these products, with several in various stages of development and regulatory approval processes.

Technological Platform and Innovation

Proprietary Technologies

Flamingo Pharmaceuticals utilizes state-of-the-art manufacturing facilities accredited by international regulatory bodies, ensuring the production of high-quality pharmaceutical products.

Significant Scientific Methods

The company employs advanced scientific methodologies in its research and development processes to formulate generic medicines that meet international quality standards.

Leadership Team

Key Executives

Ashwin Jethalal Thacker: Director since June 23, 1986.

Pranay Ashwin Thacker: Director since June 8, 2021.

Chhotulal Rawa Bhagwat: Director since October 25, 2022.

Meena Sanjiv Kapadi: Director since September 28, 2022.

Parth Ashwin Thacker: Director since November 10, 2023.

Competitor Profile

Market Insights and Dynamics

The global pharmaceutical industry is characterized by rapid growth, technological advancements, and increasing demand for generic medicines. Companies like Flamingo Pharmaceuticals are well-positioned to capitalize on these trends by offering cost-effective and high-quality pharmaceutical products.

Competitor Analysis

Flamingo Pharmaceuticals faces competition from several companies in the pharmaceutical sector, including:

Claris Lifesciences: Engages in the manufacture and wholesale of drugs and pharmaceuticals worldwide.

Blue Cross Laboratories: Provides healthcare and pharmaceutical products.

Aimil Pharmaceuticals: Manufactures and distributes pharmaceuticals.

Inventia Healthcare: Specializes in manufacturing oral solid dosage forms.

Strategic Collaborations and Partnerships

Flamingo Pharmaceuticals has established strategic partnerships to enhance its market presence and manufacturing capabilities:

Flamingo Pharma (UK) Ltd.: A wholly owned subsidiary established in 2014, focusing on the acquisition, development, and marketing of generic medicines in the UK and Europe.

Operational Insights

Flamingo Pharmaceuticals operates with a workforce of approximately 552 employees as of April 8, 2024. The company maintains a strong distribution network to ensure the global availability of its products.

Strategic Opportunities and Future Directions

Flamingo Pharmaceuticals aims to expand its presence in regulated markets, enhance its contract manufacturing services, and continue developing a diverse portfolio of generic medicines to meet the evolving healthcare needs worldwide.